The Case For Hims & Hers: Diversification And Growth Beyond Semaglutide
Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.
The Manila Times16h
Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts
Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 million; GraftAssure RUO assay launched July ...